Medicare will not cover weight-loss drugs in 2026 after all
A proposal from late 2024 to let Medicare and Medicaid pay for obesity drugs was dropped from the final rules for 2026.
Who feels it
-
Patients
Rethink
If you have Medicare and no diabetes or heart diagnosis, coverage for weight loss stays closed.
-
Payers
Rethink
Public budgets avoid a large cost for now.
-
Sellers
Adjust
A setback for makers who had hoped for a large new market.
-
Prescribers
Worth knowing
Coverage still depends on a covered diagnosis such as diabetes or heart disease.
-
Pharmacies
Worth knowing
No new volume from Medicare for obesity alone.
What was dropped
In November 2024 the outgoing administration proposed that Medicare and Medicaid treat obesity as a disease for drug coverage. That would have opened coverage of drugs like Wegovy and Zepbound for weight loss.
In April 2025 the new administration published the final rules for 2026 without that change.
What stays covered
- Use for type 2 diabetes remained covered.
- Use to lower heart risk in people with heart disease and obesity remained covered where the label allows.
Why it matters
Older adults are one of the largest groups with obesity, and many cannot pay cash prices. For them, the decision kept the door shut.
What came later
The question returned in November 2025 through a different route, a price deal with the makers. See our coverage of that deal.
Source Centers for Medicare & Medicaid Services, final rate announcement for 2026, 4 April 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
